DexCom, Inc. (DC4.DE)
| Previous close | 116.76 |
| Open | 116.76 |
| Bid | 108.56 x N/A |
| Ask | 108.86 x N/A |
| Day's range | 116.76 - 116.76 |
| 52-week range | 71.47 - 131.78 |
| Volume | |
| Avg. volume | 246 |
| Market cap | 46.434B |
| Beta (5Y monthly) | 1.22 |
| PE ratio (TTM) | 82.23 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM
SAN DIEGO, May 29, 2024--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems. Tandem Mobi, the world’s smallest, durable automated insulin delivery (AID) system1, launched in the United States earlier this year.
- Business Wire
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO, May 29, 2024--DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th.
- Business Wire
Dexcom Launches Innovative New Sensor as Groundbreaking Report Reveals Alarming Rates of Anxiety and Depression in Those With Type 2 Diabetes
LONDON, May 20, 2024--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM device that easily tracks real-time glucose readings to help improve diabetes management, and the Dexcom State of Type 2 Report. The report is a first-of-its-kind look at the Type 2 landscape today and examines the preferences and behaviours of those living with the condition, as well as their caretaker
